Disease area	Disease feature 	Disease feature 1	Disease feature 2	Disease feature 3	Cellular Input	Model	Category	Type	Cells	Cell culture type	Cell culture dimensions	3D type	Ex vivo	Applications	Biological endpoints	Throughput	Potential	Relevance		Status	Content	Predictive
Acute B Lymphoblastic Leukemia	Adoptive Cell Therapy	adoptive cell therapy	 anti-cancer therapy	anti-cancer therapy	293FT	 721.221.AEH	In silico	Algorithms	Immortalized cells	Coculture	2D	n/a	Biopsies	Diagnosis of disease	 Bcl-2 and cIAP-2 , citotoxicity, TNFalpha, Apo3L and FasL, NF-kappa B 	High	No	Direct		Proof of Concept	High	No
Acute Lymphoblastic Leukemia	Allele population study	adoptive immunotherapy	 anti-cancer treatment		Activated iNKT cells, CAR-T cells	 aAPC/mOKT3 cell (source K562), NALM-6	In vitro	Cell free	Immortalized cells / primary cell culture	Culture	2D/3D	Organoids	n/a	Diagnosis of disease Model/method dev - theor	 BETi and CTLA-4 inhibitor effect and correlation	Low	Yes	Supportive		Proof of Concept/Qualified externally	Low	Yes
Acute Myeloid Leukemia	Angiogenesis	allele population study	 biomarkers		Adaptive NK Cells	 B16-F10 melanoma	In vitro/In silico	Cell free / Ex vivo	Immortalized cells / Stem cells	Culture / Coculture	3D	Scaffolds	Organ slice	Disease mechanism (exp/theor)	 Cancer Cells and T Cells	Medium				Proof of Concept/Qualified internally	Medium	
Anaplastic Large Cell Lymphoma	Anti-Cancer Therapy	angiogenesis	 Cancer and patient classification		autologous T cells,	 CD3(+) CD8(+) T cells		Cell free / Simulation	n/a	MPS	n/a	Spheroids		Disease mechanism (exp/theor) Disease therapy dev	 CD25 and TRAIL R2/DR5					Qualified externally		
Anaplastic Thyroid Carcinoma	Anti-Cancer Therapy/Immunomodulation	anti-cancer drug delivery system	 cancer initiation and dev		B cells,T cells 	 H460 (lung), LNCaP (prostate), MCF-7 (estrogen receptor positive breast cancer) and MDA-MB-231 (triple negative breast cancer) 		Cells	Primary cell culture	n/a				Disease mechanism (exp/theor) Drug dev/testing	 CD3 and CD8, correlation					Qualified internally		
B-Cell Malignancies	Anti-Cancer Therapy/Immunotherapy	anti-cancer drug design and discovery	 chemiotherapy		CAFs	 HCC-1187, HCC-70, BT20, MCF-7, MDA-MB-231, BC		Cells / Cell free	Primary cell culture / Stem cells					Disease mechanism (exp/theor) Model/method dev - exp	 CD8+ T cell proliferation, induction of MDSCss					Qualified internally/Qualified externally		
Bladder Cancer	Biomarkers	anti-cancer therapy	 drug design and discovery		CAR	 HCT-116		Cells / Computational	Primary cell culture / Stem-cell like					Disease mechanism (exp/theor) Model/method dev - theor	 DEFA6, ABCB1 and GAL, mutational profile,ALDH1							
Bladder Urothelial Carcinoma	Cancer classification	anti-cancer treatment	 immunoclassification		CAR, NK92	 HCT-116, HT-29, RKO, SW480, and SW620		Cells / Ex vivo						Disease therapy dev	 dynamics between the bacillus Calmette-Guarin (BCG) vaccine concentration, immune-system and tumor cells							
Breast Cancer	Cancer initiation and develop.	antibody dev	 immunomodulation		CD27 memory cells	 HepG2, PLC/PRF/5, and Hep3B		Cells / Ex vivo /Computational						Disease therapy dev Drug dev/testing	 IL-10 and TGF- receptors, citotxicity							
Breast Cancer, Head And Neck Squamous Cell Carcinomas	Cell isolation and processing	autologous adoptive cell therapy	 immunoomdulation		CIK cells	 K562 and NB4		Cells / Mathematical						Disease therapy dev Model/method dev - exp	 IL-12 and GM-CSF expression							
Breast Cancer, Non-Hodgkin’S B-Cell Lymphoma	Chemiotherapy	biomarkers	 Immunotherapy		CIK, DC-CIK	 KLM-1 and T3M4, Panc-2 		Cells / Simulation						Disease therapy dev Model/method dev - theor	 IL12p70 and IFN-gamma, P38, MACD, migration							
Breast Cancer, Ovarian Cancer	Drug design and discovery	cancer classification	 microenvironment		CIKs	 LNCaP, Du-145, 22RV1		Computational						Drug dev/testing	 let-7a and let-7b , D3 + , CD8 + , CD45RO (PTPRC) + , and FOXP3 + cell densities, correlation							
Breast Cancer, Ovarian Cancer, Gastric Cancer, Esophageal Cancer Transformed Embryonic Kidney And Retinoblast Cells	Gene therapy	cancer identification and classification	 microenvironment 		CIKs, CAR-T	 MDA-MB-231, BT-474		Ex vivo						Drug dev/testing Model/method dev - exp	 MMP-9, IDO, apoptosis, GM-CSF, TNF-α, and IFN-γ							
Breast Cancer, Prostate Cancer, Lung Carcinoma	Genomic landscape	cancer initiation and dev	 patient immunoprofile		Complement Factor H Antibodies	 renal cell carcinoma cells RCC4, UMRC2, Caki-2, A-498 and 786–0		Ex vivo / Computational						Drug dev/testing Model/method dev - theor	 NY-ESO1, multiple members of the MAGE and SSX families and NY-SAR35, SSX2, epigenetic profiles, RNA profile							
Breast, Colon And Prostate Cancers	Identification and characterization of circulating cells or DNA	cell isolation and processing	 patient stratification		CTLs	 SK-BR-3		Mathematical						Model/method dev - exp	 PD-L1, clinical outcome correlation							
Burkitt’S Lymphoma	Immunomodulation	chemioimmunotherapy	 radiotherapy		CTLs 	 SK-BR-3 (Her2(+)) and MDA-MB-231 (Her2(-)).		Simulation						Model/method dev - exp Model/method dev - theor	 TNF, IFNG and FOXP3 methylation, correlation							
Cervical Cancer	Immunoprofiling	Chemiotherapy	 virotherapy		CTLs, DCs	 T cells 								Model/method dev - theor	16INK4a, CD56, correlation							
Cervical Cancer 	Immunotherapy	CIK cell infusion therapy			cytokine induced Killer cells (CIK)	 U251, A172 (IL-13R2 +ve) and T98G (IL-13R2 -ve) glioma cell lines								Model/method qualification	1A3 , apoptosis							
Cholangiocarcinoma	Immunotherapy/Anti-cancer therapy	drug design and discovery			cytokine-induced-Killer	 U87, HEK293T 									4-1BB, CD3, CD4, CD8, CD16, CD56, CD57, Granzyme B, T-bet, γδ T-cell receptor (TCR), CD27, CD28, CD45, CD45RA, CD45RO, CCR7, BTLA , PD-1, KLRG1, IFNγ secretion, TILs growth and CD8+ count							
Chronic Lymphocytic Leukemia	Microenvironment	gene therapy			DC	22RV1, Du-145, MCF-7, H460, SUM149									4-1BB, T cells count, citotoxicity, IFN-gamma							
Chronic Myelogenous Leukemia	Patient Stratification	genomic landscape			DC cells	253J, T24									ABCB5, cytokines,  IFN‐γ, TNF-α							
Chronic Myeloid Leukemia	Radiotherapy	identification and characterization of circulating cells or DNA			DCs	26 NSCLC cell lines (list not available)									ADAM10, NKG2DLs and ADAM10 and ADAM17, degranulation, citotoxiciy							
Clear Cell Renal Cell Carcinomas	Tumor characterization	immunomodulation			DCs, citotoxic Lymphocytes	293F and 293FT,  PC10, H226, LK2 and LC-1, A-549, REPF-LC-MS, VMRC-LCD and ABC-1, Biopsies									ADAM17, cell viability							
Colon Adenocarcinomas	Tumor classification	immunoprofiling			DCs, T cells	293T									ADCC, CD16a or FcγRIIIa, proliferation, citotoxicity							
Colon Adenocarcinomas , Cervix Adenocarcinoma , Gastric Tumor Cell, Pancreas Adenocarcinoma	Virotherapy 	immunotherapeutic agents design and discovery			DCs, T-cells	293T, U87-MG (ATCC, HTB-14), LN-18 (ATCC, CRL-2610), PC3 (ATCC, CRL-1435), MDA-MB-231BR									ADCC, degranulation							
Colon Cancer		immunotherapy			dendritic cell lysate	3 medulloblastoma cell lines (18), D283 and D341, and 2 PXA cell lines, 645 and 2363									Adenosine A2a Receptor, citotoxicity, PD-1							
Colorectal And Prostate Cancer		immunotherapy (photoimmunotherapy)			Dendritic cells	3AO, A2780, HO-8910, OVCAR-3 and SKOV-3, K562									AK2 and STAT1, miR-21							
Colorectal Cancer		landscape 			Dendritic cells (DCs) and cytotoxic T-Lymphocytes (CTLs)	55 cell lines, 139 Biopsies									AKAP4							
Craniopharyngioma 		microenvironment			dendritic cells, T-Regs, CTLs	55 cell lines, Biopsies									alpha-SMA, CK19, morphology, citotoxicity							
Cutaneous Angiosarcoma		Patient Stratification			exosomes	55 patient-derived melanoma cell lines									AMPK/Akt/mTOR pathway, IL-2, IL-10, insulin-like growth factor (IGF)-beta and vascular endothelial growth factor (VEGF), proliferation, invasion							
Cutaneous T-Cell Lymphoma		Radiotherapy			gamma delta T cells	8505-c, TPC1, BHT101-5									Ang, RNH1, cytotoxicity							
Diffuse Large B-Cell Lymphoma		Radiotherapy immunomodulation			HCT- 116 and MCF-7 lysates	9 CTC primary cell lines									angiogenesis,  cell-adhesion							
Edwig Sarcoma, Neuroblastoma		Radiotherapy immunotherapy			hepatic stellate cells	A-253 cells, FaDu cells, IMC-3, M108, K562-MSLN									angiogenesis, caspase-3, p53, proliferation,  IL-6, TNF-α and IFN-γ, and a EGFR, CD4, CD8							
Endometrial Cancer		T-cell therapy			hepatocellular carcinoma cell	A-549									Angiogenin, MMP9, TIMP2, angiogenesis, degranulation, cell-adhesion, ÑK secretome							
Epithelial Cancers		Tumor characterization			HLA-A*02:01 primary cells	A-549 									angiopoietin/Tie2 pathway, Ang1 and Ang2, ICAM-1, proliferation, viability							
Esophageal Cancer		Tumor classification			Human monocyte-derived DC, normal allogeneic T Lymphocytes (MLR)	A-549 (lung), HCT-116 (Colon) and MCF-7 (breast)									antibody profile 							
Gastric Cancer		virotherapy 			Human peripheral blood Lymphocytes (PBL), TILs	A-549 and LETP-2									antigen presentation capacity, phagocytic activity, chemotaxis capacity, T-cell proliferation and cytokines release, migration capacity and T cell proliferation							
Gastrointestinal Cancer					Human sera	A-549 and NCI-H460									antigene affinity							
General					HUVEC	A-549, H1299, SPC-A-1, and H1975									antigene presentation							
General 					infiltrating Lymphocytes 	A-549, H23 or H838									antigenome profile, immuno profiling, correlation, CCR8, BCMA 							
General (Breast Cancer As Instrumental)					iNKT 	A-549, HT-29, and RAMOS									apoptosis , MYCN, citotoxicity							
General (Cell Lines As Instrumental)					Jurkat T cells	A-549, NCI‐H1299									apoptosis, 							
General (Cells As Instrumental)					LAA-expressing hybridoma cells	A-549, PC9, HCC-827, H1975, H1993, BEas-2B									apoptosis, citotoxicity							
General (Colon Cancer As Instrumental)					liquid Biopsies (sera)	A2780 (ovarian) and HCT-116 (Colorectal)									apoptosis, Colony formation, TIM-3							
General (Melanoma As Instrumental)					lymphatic endothelial cells (LECs)	A2780 and SKOV-3 									apoptosis, cytokines, 							
General (Ovarian As Instrumental)					Lymphocytes	A375, A2058, G361 , SK-MEL-28									ARMC3, DDX53, FTHL17, GAGE1, MAGEA11, SYCE1, TCP11, and XAGE1							
General (Renal Cell Carcinoma As Instrumental)					Lymphocytes, CIK	A431, Colo320, SW480, Caco-2, SW620, HT-29									B cell-associated protein 31 (BAP31), RNA profile, correlation							
General Metastatic Cancer					lysosomes	ACHN cells									B7-H1 and B7-H4							
Glioblastoma Multiforme					M phi 1 supernatant, T cells	aDu									B7-H1, Colony formation, 							
Glioblastoma, Breast Cancer Brain Metastasis					macrophages	AGS and SGC-7901									B7-H1, invasion							
Glioma					macrophages 	AML-M4, AML-M5									B7-H4, citotoxicity, t-cells infiltration							
Haematological Cancer					MDA-MB-468 and MCF7	autologous sCSC									BIRC5, CA125, CEA, DDX43, EPCAM, FOLR1, Her-2/neu, MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, MUC-1, NY-ESO-1, PRAME, p53, TPBG, TRT, WT1							
Head And Neck Cancer					Membrane vesicles and TDEs from multiple head and neck cancer cell line	B cells, Raji cells, Z138 cells									blood mMDSCs to DC ratio							
Head And Neck Squamous Cell Carcinoma					mestrual fluid	B-lymphoid cell, Dakiki, EBV, WAS2, WAS4, WAS R86H cell lines 									c-SRC kinase (CSK) , ERK, pMHC-induced IL-2 release							
Hepatic Cancer					MMC	B16-F10,  LCC1									calreticulin (CRT), correlation							
Hepatocellular Carcinoma					monocyte-derived DCs (MoDCs)	B16-F10, BHK-21, CT-26									cAMP, Notch receptor, proliferation, spheroid formation							
Human Leukemia, Mesothelioma					Monocyte, HUVEC	B76 and MDHA-2774									cancer growth							
Laryngeal Cancer					monocytes	Biopsies									cancer testis antigenes							
Leukaemia					Monocytic MDSCs	Biopsies (lymphoid cells)									CCL-1, citotoxicity							
Leukaemia And Lymphoma					myeloid and endothelial cells, T cells	Biopsies and sera form CRC patient									CCL17 and CCL22/CCR4							
Leukaemia/Lymphoma/Myeloma					Myeloid-derived suppressor cell	Biopsies,  Hs 936.T , A2058 and Colo679,  WM983(B), 451 Lu, WM3918, and WM3912 ,  UACC1273 									CCL21 and IFNgamma							
Leukoplakia					Myeloid-derived suppressor cells (MDSCss)	Biopsies,  SKO-007(J3), U266, RPMI 8226, ARP, ARK, OPM-2, and LP-1									CCR10, citotoxicity, chemiotaxis, CCL27, CCL28							
Liver Cancer					n/a	Biopsies, BIU-87									CD137, ADCC, Fc gamma-RIIIA, citotoicity							
Liver Cancer, Leukemia					NK	Biopsies, Capan-2 (HLA-A2þ), AsPC-1 (HLA-A2 ), Panc-1 (HLA-A2þ), and MIA-PaCa-2 (HLA-A2 )									CD14, CD3, IFN-gamma, cytotoxicity							
Lung Adenocarcinoma					NK cells	Biopsies, HEK293T, HEK-PSCA									CD16, ADCC							
Lung Cancer					NK cells, gamma delta T cells, alpha beta T cells	Biopsies, HeLa									CD16, IFN-gamma, citotoxicity							
Lung Squamous Cell Carcinoma					NK cells, NK-92 cells	Biopsies, HL-60, KG-1, K562, MOLT-4, A431									CD169							
Lung, Cervical Carcinoma, Leukemia And Pancreatic Cancer					NK-92	Biopsies, K1, BCPAP, 8505-c, 8305-c, Nthy-ori 3-1									CD1d , cell cycle, mitochondrial membrane depolarization							
Lymphoma					NK-92 	Biopsies, liquid Biopsies									CD1d,  Erk/MAPK , CD80, B7-H2							
Medulloblastoma, Pleomorphic Xanthoastrocytoma					NK-92MI	Biopsies, MCF-7, BT-474 and ZR-75-1									CD20, TNFR1 , cell death							
Melanoma					NK92 	Biopsies, MGC-803, NCI-N87 and AGS									CD22							
Melanoma And Haematological Cancer					NKT cells	Biopsies, NCI-N87, AGS, SNU216, SNU668, and SNU719, YCC3, YCC10, and PC9 									CD25 and DR5							
Melanoma, Breast Cancer, Multiple Myeloma Cell, 					NKT-like Cells 	Biopsies, OV-90, SKOV-3 and OVCAR-3, CaOV-3									CD25, CD69, 4-1BB, and OX40, IFN-gamma, 							
Metastatic Melanoma					PBMCs	Biopsies, serum and peripheral Blood									CD3, CD8, FOXP3, and CD68, Infiltrating Lymphocytes and Macrophages							
Monocytic Leukemia, Myelomonocytic Leukemia					PBMCs 	Biopsies, several immortalized cell lines, NK cells									CD3(+) T cell proliferation, MDSCss titer							
Multiple Myeloma					PBMCs - CAR-T	Biopsies, SW620									CD3/CD28, IL-21, CD3, CD28, CD4(+) and CD8(+) memory stem T cells							
Multiple Myeloma And Oral Squamous Cell Carcinoma					PBMCs, macrophages derived from U937 	Biopsies, T24, UM-UC-3, J82, 5637, SW780, and RT4									CD33-CD3							
Myeloma					PBMCs, monocytes and dendritic cells (DCs)	Biopsies, TAMs									CD38							
Nasal Natural Killer/T-Cell Lymphoma					PBMCs, T-cells	Biopsies, TILs									CD38, CD101, PD1, CD8							
Nasopharyngeal Cancer					PHA, K562	BT-474									CD38, cytotoxicity							
Neck Squamous Cell Carcinoma					primary B-cells	BT-474, BJAB									CD40, CCR2							
Neuroblastic Tumors					RAW 264.7 	BT-474, CAMA-1, MDA-MB-435, MDA-MB-436, SK-BR-3, CaOV-3, OVCAR-3, SKOV-3, N87, OE19, transformed embryonic kidney 293, retinoblast 911 cells, JIMT-1, HEY,  MKN-28, MKN-45 									CD41 and CD81, citotoxicity							
Neuroblastoma					SKOV3, OVCAR-3, A2780, HEK-293T	C1 cells									CD44, CD133, Nanog, and Oct3/4, and immunosuppressive molecules HLA-G and -E							
Neuroblastoma, Melanoma 					supernatants	Calu-6, NCI-H1299, HT-29,HepG2, 1321NI									CD56, NKG2D and NKp44							
Neuroendocrine Tumor					T-cells	CaSki , SiHa									CD64, MAP, citotoxicity							
Non-Hodgkin Lymphoma					T-cells, DCs, B cells	CD4(+) T cells 									CD68 (pan-M phi), CD80 (M1 M phi), CD163 (M2 M phi), CD4 (helper T cells: Th), CD8 (cytotoxic T cells), CXCR3, CCR5 (Th1), CCR4 (Th2), signal transducer and activator of transcription (STAT1), phosphorylated STAT1 (pSTAT1) and chemokine CXCL9, correlation							
Non-Muscle Invasive Bladder Cancer					T-cells, NK cell, myeloid cells	CD8+ T cells									CD8 and PD-L1							
Non-Small Cell Lung Cancer					T-cells, PBMCs	CHO-A1,HEK-A2B, HeLa-A2A ,HeLa-A3, lung Cancer tissue									CD8(+) T-cell expansion, RNA profiling, 							
Non-Small Cell Lung Cancer, Lung Adenocarcinoma					T-cells, PBMCs and monocytes 	CIK cells									CD8(+) T-cells, dendritic cells and monocytes, LAG3, PD-1, TIM3 and CTLA4, correlation							
Oral Squamous Cell Carcinoma (Oscc)					T-cells, TILs	CIK, NK, DCs									CD83, HLA-DR, CD80, CD86, IFN-g							
Oral Squamous Cell Carcinoma (Oscc) 					T-Regs	CL-188, HTB-39, and HTB-37, Biopsies									CD86, CD21, IgD, CD27, correlation							
Oropharyngeal Squamous Cell Carcinoma					T2	CNE2									CD86, IL-10, TNF-α							
Osteosarcoma					THP-1, Jurkat, HL-60	Colo 205, HT-29 and Colo 320, Colon adenocarcinoma cells, HeLa cervix adenocarcinoma cells, MKN45 gastric tumor cell and Bx-PC3 pancreas adenocarcinoma									CDCP1							
Ovarian Cancer					THP-1, U937	Colon adenocarcinoma cells LS174T and LoVo, MRC-5 normal fetal lung fibroblast cells, CCD-18Co a normal Colon fibroblast cell line									CEA-IL2v plasma concentrations							
Ovarian Cancer, Breast Cancer					TILs	CRC cells									Cell Growth, Viability, EGFR, Erk1/2, and Akt							
Pancreatic Adenocarcinoma					TILs, CTLs	CTLs									cell homing, immune invasion of tumor spheroids, and spheroid cytotoxicity							
Pancreatic Cancer					TILs, TANs	DCs									cell infiltration, correlation							
Papillary Thyroid Cancer					TREG, CTL, NK	DLD-1, HCT-116, SK-MEL-28, A2058 and CHO-K1, NCI-H1975, ES-2, MDA-MB-231, Biopsies									cell infiltration, PD-L1, PD-1							
Penile Squamous Cell Carcinoma					tumor lysate	DM6, DM440, and DM443, DU54 									cell proliferation, apoptosis							
Primary Acute Lymphoblastic Leukemia					UB protein extracted from tumors	Du-145, PC3, and LNCaP									cell proliferation, cytotoxicity							
Primary Multiple Myeloma					V45.2.' T-cells	Eca-109 									cell size, cellular radioactivity distribution							
Prostate Adenocarcinoma					γδ T-cells	EL4 cells									cell viability							
Prostate Cancer						EOC 									cell-cell contact, immuno response, apoptosis							
Prostate Cancer, Breast Cancer						FaDu, CAL27, CCL-138									chromogranin A (CGA), CD56, synaptophysin (SYN), CD3, and PD-L1							
Prostate, Breast, And Lung Carcinoma						g SKMES-1, Calu-1, A-427, A-549, and SKLU-1, MRC-5, 3A5A, 1.3.11, 1.3.15, 3B1A, AJG-1, OSJV-1, CDS-1, MRLO-1, MRLO-2, and RCC1-20 NSCLC 									citokynes, IL12							
Pulmonary Lymphoepithelioma-Like Carcinoma						GL261 and CT-2A GBM-like									citoticity, TGF-ß, PDL-1							
Renal Carcinoma						H1299 and H226B									citotoxicity							
Renal Cell Carcinoma						H1650, H1650GR 									citotoxicity on Cancer stem cell							
Renal Cell Carcinoma 						H2087 (ATCC/CRL-5922), HeLa and Panc-1									citotoxicity,  IFIN-gamma							
Rhabdomyosarcoma						H441, U937, T2, H2023,  H441,  DFCI024, DFCI032,  H1299,  HCC-2935									citotoxicity,  IL-35, TGF-beta and IL-10, Foxp3							
Rhabdomyosarcoma, Breast, Prostate And Pancreatic Cancer						H460 and H1703									citotoxicity, ADCC							
Salivary Adenoid Cystic Carcinoma						HCC-1428, MCF-7, T47D, BT-474, UACC-812, ZR-75-30									citotoxicity, antibosy stability							
Salivary Gland Cancer						HCC-2935, NCI-H1993, H522									citotoxicity, apoptosis, migration							
Sarcoma						HEK 293T, LS174T									citotoxicity, autophagy, apoptosis, PHLDA1 , apoptosis							
Serous Ovarian Cancer						HEK293									citotoxicity, Bcl-x, Her2, Her3 and MUC16							
Small Cell Lung Cancer						HEK293, HeLa, MKN45, Jurkat clone E6–1, U937 									citotoxicity, binding and internalization behavior of 425(scFv)-ETA							
Soft Tissue Sarcomas						HEK293, MCF-7, A-549, HO-8910PM, HeLa, HepG2									citotoxicity, calcitonin receptor (CTR) , drug uptake							
Squamous Cell Lung Carcinoma						HEK293, SKOV-3.ip1, SKOV-3.ip1-luc, OV-4 									citotoxicity, CD20							
Superficial Bladder Cancer						HEK293T									citotoxicity, CD83, CD86 and major histocompatibility complex (MTIC)-II, LDH, FOXP3 , IL-12 and IFN-gamma 							
T-Lymphoblastic Leukemia And Lung Carcinoma						HEK293T , A-549									citotoxicity, cell viability, proliferatio, migration, PD-L1							
Thyroid Cancer						HeLa									citotoxicity, citokines							
Urothelial Bladder Cancer						Hep-G2, QUY-703, L02									citotoxicity, CTLA-4/CD152 and PD-L1/CD274, CD70, CD275/ICOSL, CD134L/OX40L, and CD137L/41BBL, IFN-gamma							
						HepG2 and K562									citotoxicity, degranulation and cytokine production							
						HepG2 cells, HCC cells									citotoxicity, drug internalization, 							
						HGCC									citotoxicity, eIF2 , IFN, IRF3, 							
						HH, H9, Hut78, MJ, and Hut102 patient-derived									citotoxicity, FN-gamma, TNF-alpha,CD69							
						HL-60 pro-monocytic									citotoxicity, HER2, degranulation							
						HL-60, macrophages									citotoxicity, HLA class I expression							
						HL60 and MOLT4									citotoxicity, IFM-gamma,  HLA-A*02:01/CT37							
						HN4, HN6, HN30									citotoxicity, IFN-gamma							
						HOS, U2OS									citotoxicity, IFN-β and LDH 							
						HSB-2, Ramos, and Daudi cells									citotoxicity, IFN-β ELISA and LDH 							
						HSC-2, HSC-3, and HSC-4									citotoxicity, IFN-γ 							
						HSC-3, OSCC3, SCC-14a/b, SCC-4, SCC1, CAL27, HIOEC-B (HB), HaCaT									citotoxicity, infiltration, spheroid morphology							
						HT-29									citotoxicity, internalization							
						HT-29 and DLD-1									citotoxicity, mAB internalization							
						HT-29, liquid Biopsies									citotoxicity, mogration							
						HT-29, SW620									citotoxicity, Nipsnapl and glycine-tRNA ligase (GRS)							
						HT-29, SW62D									citotoxicity, PD-1							
						hTERT-HPNE and pancreatic cancer cell lines									citotoxicity, PD1/PDL1 axis							
						Human breast (MDA-MB-231 and MCF-7), Colon (SW620, SW480, and Colo205), and prostate (LNCaP) tumor cell lines									citotoxicity, proliferation							
						Human cutaneous melanoma cell lines (Mel 195, 275, 313, 346, 116, 120, 514, 142, 237, 403, 458, 345, 599, and 261) were generated from surgically removed metastatic lesions from melanoma patients, as previously described. Human hematological cancer cell lines (Daudi, HL-60, NALM-6, Raji, U-937, KG-1a, Jurkat, JY, Ri-1, K562) w									citotoxicity, proliferation, survival, antigen 6 complex, locus G6D (LY6G6D) , JAK/STAT5							
						Human iPSCs derived from melanoma TILs									citotoxicity, proliferation, TNF-alpha, IL-1 beta, IL-6 and PEG(2)							
						Human neuroblastoma cell lines LA-N-1 and SK-N-SH and a lymphoblastic lymphoma cell line (SupT1) 									citotoxicity, prolifetarion							
						IMR-32, CHP-134									citotoxicity, protein inhibition, aploid nuclei							
						IMR-32, LA-N-1, CHP-134 									citotoxicity, protein profile							
						IMR-32, SK-N-BE, SH-5YSY, LA-N-6									citotoxicity, Runx2							
						IMR-32, SK-N-FI, mel526 									citotoxicity, secreted IL2 and IL6, IL3, TNFα, and IFNγ							
						iNKT									citotoxicity, T cell activation							
						iNKT cells									citotoxicity, viability							
						Invariant Natural Killer T (iNKT), hESC, H1  									citotxicity							
						ISOS-1, HAMON, Biopsies									citotxicity, Colony formation, mutation profile							
						Jurkat E6.1, Molt-3, KBM7, K562, THP-1, U266, TK6, HP, VB, BV, KÖ, CM, PH									citotxicity, Cytokine and Chemokine, Colony formation							
						Jurkat T									citotxicity, STEAP1							
						Jurkat, CHO-K1, HeLa, HCC-827, PC3, NCI-H2023, 4 T1, B16-F10, and CT-26									citoxicity							
						K562 									correlation							
						K562 cells									correlation, immune cell desity							
						K562 cells, A431 									correlation, LAMC2 , lymph node metastasis, migration, invasion							
						K562 or Daudi									correlation, NKp30 and NKp46, citotoxicity, degranulation, DNAM-1, CD57, CD10							
						K562 Raji									correlation, proliferation, apoptosis, migration, invasion, 							
						K562, Daudi, Raji, UB2MT, C1AK									correlation, T cell, cytokine							
						K562, U937									correlation, T helper type 1 (Th1), Th2, Th17, and regulatory T (Treg) cells densities							
						KG-1a									CT45							
						KKU-055, KKU-100, and KKU-213 									CTCS presence							
						L60, SK-BR-3, T47D, HCT-116, U937 and U251									CTL ratio,  WT-1, PRAME, MAGE, h-TERT 							
						liquid Biopsies									CXCL9 and CXCL10, CD3, CD56 and FOXP3 , COX, TILs count, Chemokine regulation, correlation							
						liquid Biopsies (metastatic pancreatic cancer patients' Blood;)									CXCR3, CXCR4 and CXCR6, citotoxicity, NK migration							
						liquid Biopsies, LAPC4, PC3, Du-145, 22rv1, LNCaP,RWPE-1									CXorf61, cytotoxicity							
						liver metastasis									Cytokine , citotoxicity							
						LLC.OVA									Cytokines							
						LNCaP, Du-145									cytokines secretion, citotoxicity, T cell activation							
						LNCaP, MDA-MB-231									Cytokines, cytotoxicity, PD-L1, IFNγ 							
						LNCaP, MDA-MB-231, NCI-H1703, JHC7									cytotoxicity							
						LoVo, HCT-116									cytotoxicity, apoptosis, Hsp90, viability and Colony formation							
						LP-1, OPM-2 and RPMI8226									cytotoxicity, cytokines							
						Lymphocytes									Cytotoxicity, degranulation, and cytokine release, CD16, CD56							
						M171, M425 and M579									cytotoxicity, HER2, CD79b, Calreticulin , HMGB1, apoptosis, CXCL10 							
						M2-derived Kasumi-1									cytotoxicity, HSPA, endoplasmic retuculum stress, autophagy, apoptosis							
						mast cells									cytotoxicity, IL-2, IL-15, IL-18, Ki67							
						MBA-MB-231									Cytotoxicity, IL2Rα, CD56, CD69, IL6, IL12p70, TNFα							
						MCF-10A									cytotoxicity, secreted citokines							
						MCF-7									Degranulation , MICA/B and NKG2D-Fc fusion protein, HLA-I, citotoxicity							
						MCF-7,  Natural Killer cell, and cytotoxic T Lymphocytes									degranulation, CD107, cytotoxicity, IL-15SA/IL-15RA, TGF-β1, SMAD2/3, EGFR							
						MCF-7, HCC-1428, T47D, BT-474, UACC-812, ZR-75-30									degranulation, citotoxicity, 							
						MCF-7, HCC-1954									Dendritic cell-derived exosomes, citotoxicity							
						MCF-7, HDFa									densities of Th1, effector-memory T cells, T cells proliferation , PD1-PDL1, IMMUNOSCORE, satellite stability, correlation							
						MCF-7, HUVEC									Disialoganglioside							
						MCF-7, MCF-7 TamR, T47D, SK-BR-3, MDA-MB-231									DNA profile, IFNγ							
						MCF-7, MDA-MB-231, SK-BR-3, BT-474									DNA profile, mutational profile							
						MCF-7, SK-BR-3 and MBA-MB-231									DNA profile, NRAS mutation, correlation							
						MCF-7, T47D									DNA profile, PD-L1, PD-1							
						MCF-7, ZR-75-1, and MDA-MB-231, NHL									DNa profile, proteome profile, immuno profile,							
						MCF‐10A									DNA profile,SCC4, SCC15, and SCC25							
						MCW670, Panc-1									DNA profiling							
						MDA-MB-231									DNA sequencing, mutational profile							
						MDA-MB-231 and T47D									doses of Lymphocytes,  stability and its sensitivity o the model							
						MDA-MB-231, HCC-70, MCF-7									drug delivery and penetration							
						MDA-MB-231, MDA-MB-435S, MDA-MB-453, SK-BR-3, ZR-75-1, T47D, and MCF-7,									drug internalization, citotoxicity, LAMP1, ROS levels							
						MDA-MB-231, MDA-MB-468									drug uptake							
						MDA-MB-231, MDA-MB-468, and MCF-7, 293T,Phoenix cells									e B7-H3-specific mAb 376.96 staining							
						MDA-MB-231; MCF-7; and MCF-10A									E2F-1, citotoxicity, CIK							
						MDA-MB-435, HeLa, Colo-205, Du-145									EFGR, HER2, and PD-L1, CCL2, CCL21, VEGF and CXCL1							
						MDA-MB-453, MCF-7, MBA-MB-231									EGFR, cytotoxicity, degranulation, IFNγ, citotoxicity							
						MDA-MB-468, 231-H2N									EGFR, drug cellular uptake and localization, survival,  apoptosis/necrosis							
						MDA-MB-468, normal ductal epithelium Biopsies									endocytosis, proliferation,  cytokine and chemokine							
						MeCoP, MeTA, MeDeBO, and MeOV									EPHA2 , citotoxicity							
						MEFs 									epigenetic profile, PD-L1 and HLA-DR							
						MIA MIA-PaCa-2 and AsPC-1									epitope recognition							
						MIA-PaCa-2 									equilibrium points of the model 							
						MIA-PaCa-2 and Panc-1 , patient-derived organoids (PDOs), Biopsies									ErbB2 							
						MIA-PaCa-2, MDA-MB-231									exosome protein profiles, E6/E7, p16, and survivin, apoptosis, proliferation							
						MIA-PaCa-2, PK-45, Panc-1, KLM-1, Bx-PC3, and PK-1									expression of 18 cancer-testis antigene, correlate							
						MM									expression of CTA							
						MM.1S, U266B1, SCC4, SCC15, and SCC25									extravasation,  T-cell migration and cytotoxicity							
						MOLM-13									FAK, T cell infiltration							
						MOLM-13, MOLM14, and HL60									FAS, Colony formation, migration							
						monocyte-derived DCs									FOXP3,  Treg-specific demethylated region (TSDR)							
						monocytes 									gene profiling, ALG12, GUSB, RPLP0, KRBA2, and ADAT2, IFN gamma and TNF alpha							
						myeloid derived suppressor cells (MDSCss) 									Genome profiling ,new antigenes,  immunomodulatory proteins and cytokine profiling 							
						Myeloid-derived suppressor cells									genome profiling, DDB1, ERCC1, ERCC2, PRPF19, BCAT1, CDKN1B and MARK4, molecular signature							
						Myeloid-derived suppressor cells (MDSCs) 									growth of tumor cells 							
						Myeloid-derived suppressor cells (MDSCss) , T cells									Hemolysis , citotoxicity, apoptosis, migration							
						n/a									HLA-A2/MIF, citotoxicity							
						Natural Killer (NK) and CD8C T immune cells									HLA-DRA, HLA-DRB3, HLA-DMA, HLA-DMB, B2M, HLA-A, HLA-B), ADA (encoding adenosine deaminase), ADGRE5 (CD97), CD58 (LFA3), CD74 (encoding invariant chain and CLIP), CD83, CXCL8 (IL8), CXCL16, HLA-F, IL6, IL18, and KITLG, 							
						NCI-H125									HLA, IFNγ , cytokine , cytotoxicity							
						NCI-H226, NCI-H358 and NIH:OVCAR-3									HORMAD1 , correlation, PARP, ROS							
						NCI-H69, NCI-H146, NCI-H446, NCI-H82, NCI-N592									HPV status, Chemokine and cytokine							
						NCI-N87, MKN45, AGS, NUGC3, SGC-7901, MGC-803 and BGC823, and Jurkat cells, Biopsies									ICAM-1, citotoxicity							
						NK									IDO-1, cancer-immune system interactions							
						NK cells									IDO,  IL-2, IFN-gamma, perforin secretion, IL-10 and TGF-beta							
						NK cells, PBMCs									IDO, CD31, and CD105, proliferation							
						NK T cells									IDO1 inhibitors							
						NK-92									IDO1- and TDO2, WARS, IFN gamma, GCN2-peIF2 alpha-ATF4 signaling							
						NKT, DC									IDO1, methylation profile, Kyn in Human sera							
						NUGC4, HCT-116, SW620, MOLM-13									IFN-beta , PD-L1, PI3K, IFN-beta-induced							
						OPM-2, L363 and U266									IFN-gamma, RFXAP. miR-212-3p, 							
						OV-MZ-6 and SKOV-3, Biopsies									IFN-γ release, cell viability, citotoxicity							
						OVCAR-3, SKOV-3, and OVCAR-4									IFN-γ, IL-2, and IL-12p70,  oxidative and apoptotic stress, viability, prolieration							
						P815 mastocytoma cells									IFNβ 							
						Panc-1									IGF2BP3, correlation							
						Panc-1 and SW1990									IL-11, JAK/STAT3, T cells proliferation							
						Panc-1 or MIA MIA-PaCa-2									IL-13R2, IL-13, c-Jun, Fra-1, Jun-D, c-Fos, and Jun-B, JAK/STAT, 							
						Panc-1,  Capan-1									IL-15, ILR-15							
						Panc-1, MIA MIA-PaCa-2, K562									IL-17 mast cells count, correlation							
						Panc-1, Panc-2, Colo-357, SU8686, AsPC-1, MIA MIA-PaCa-2 and Bx-PC3, HPDE-E6E7									IL-17, IL-2							
						Panc03.27									IL-18. PD1, 							
						panel of solid and liquid tumors									IL-1β, TNF-α, IL-6, and PGE2, citotoxicity							
						patient-derived myeloid leukemia (AML) cells									IL-2							
						PBMCs									IL-2, CD56, CD16, NKG2D, NKp30, IFN-γ, NKp46 and increases NKG2A/CD94							
						PBMCs, Biopsies									IL-2, correlation							
						PBMCs, Bone marrow mononuclear cells									IL-2, IFNγ, citotoxicity							
						PBMCs, DCs									IL-2, IL-7 and IL-15							
						PBMCs, NK									IL-2, TILs count, IFN-gamma, PD-1 and 4-1BB							
						PC14,  LU99B, PCI6,  A172, HT-1080, MKN28, AZ-521, MCF-7 									IL-21R							
						PC3									IL-27, IL-6, IFN-γ							
						PC3, Du-145 and LNCaP 									IL-32α, metastasis, and invasion, JAK2/STAT3, N-cadherin, Vimentin, Snail, Zeb1							
						PcCL3 									IL-6, STAT3, (HLA)-DR and CD86, ARG1, COX2, CTSL 							
						PDAC, KLM-1, HCC-70,  A431/H9									IL-8							
						peripheral Blood Lymphocytes from Colon cancer patients, SK-MEL-28, HCT- 116, M1/9 melanoma and IDC Tu2									IL-8/CXCL8, MCP-1/CCL2, angiogenesis, macrophage infiltration, p65, E1A							
						peripheral Blood mononuclear cells (PBMCs), DCs (DCs) 									IL17A, cell proliferation, apoptosis							
						PNT1A, LNCaP									IL1RAcP, proliferation, citotoxicity							
						primary high-grade glioma cell line (HGG, representing glioma stem cells) SB2b									immune dynamycs							
						Pumc-91 and T24 									immune system response, IL-2							
						QU-DB (large-cell lung carcinoma) and A-549 (adenocarcinoma)									immunopeptidome profile, SLC45A2 and CTL sensitivity 							
						Raji cells									immunoprofile							
						Raji, MOLT-4, Jurkat									immunoprofile, cytokines							
						RCC cells									immunoprofiling , T- and B-cell immunosequencing							
						RCC85#21									immunoproteomic profile, genomic profile							
						RMS									immunotoxicity, citokynes							
						RPMI-8226									immunotoxicity, proteomic profiling							
						RPMI-8226, IM-9, K562, THP-1, MOLT4, CCRF-CEM, Ramos, U937									in vivo tumore-immune interactions							
						s ES-2, OVCAR-3, CaOV-3, HEY-A8, SKOV-3.ip1 and A2780 , Biopsies									infiltration							
						SACC-83 and HN13 									infiltration, citotoxicity, MIP1α, RANTES, and CD40L							
						scc-U2, scc-U8, and OSC19, A431									infiltration, fibroblast citotoxicity, T cells  activation; increased cytokine secretion, IL-2							
						SCC4, SCC15, SCC19, SCC25, SCC84, SCC92, SCC99									interaction of tumour infiltrating cytotoxic Lymphocytes (TICLs) with tumour cells							
						serum									interleukin (IL)-2, IL-7, and IL-15, ECCE,  IFN-γ and TNF-α, citotxicity							
						SET-2, BV173, 697, SKLY-16, BA25, HL-60, Meso/A24 									inverse mapping 							
						SGC-7901 									JAK/STAT pathway, PD-L1							
						SGC-7901 and AGS									killing rates of CD8+ T cell and NK cells							
						SiHa and Caski									KIR3DL1, HLA-B, correlation							
						SiHa keratinocytes									KY-CC-14/ACTR1A, KY-CC-19/TSGA2, KY-CC-12/FKBP4, KY-CC-15/PLRG1							
						SiHa, HeLa, DoTc2 4510, HPV 16 E6/E7-transformed, Ect1/E6E7									L-33, Fox3p, T-Regs density, cell proliferation, correlation							
						SK-BR-3									LAG-3, PD-11, PD-L1, infiltration of T-cells, correlation							
						SK-BR-3, A431, NCI-N87, MKN-7, AGS, JIMT-1									least effective concentration and the half-life of the drug							
						SK-BR-3, BT-474, MCF-7, MDA-MB-231, SK-OV-3									LRIG1 , correlation							
						SK-MEL-23, SK-MEL-37, ALAB, MCF-7, 734B, ARK , U266, T2-1B 									lymphatic vessel density (LVD), CD8+ T cell infiltration, INOS, IDO							
						SK-MES-1, U251, HEC-1B, SK-MEL-2									Lymphocytes telomerase activity, 							
						SK-OV-3									MAGE A11							
						SK-OV-3, HEC-1A, ovarian tumor									MAGED4B and FJX1, citotxicity							
						SKMEL-28 cells									MAP3K3, correlation							
						SKNBE(1)n and SKNMM									MAPK/ERK and NFB/RelB							
						SKOV-3									maturation and  number of CTLs, PD-L1, citotoxicity							
						SKOV-3-IP									MCF-7, ZR-75-1, and MDA-MB-231, citotoxicity, ROS, radiation-nduced transcriptional changes							
						SKOV-3, A2780, and OVCAR-3									MDSCs suppression, PDL1, DC HIL, 							
						SKOV-3, A2780, OV-90, FHIOSE118hi 									Melanoma antigen family A4 (MAGEA4), correlation							
						SKOV-3, HEK293 cells and H460 lung cancer cells									MHC class I chain-related A/B, citotoxicity, 3-BrPA, NK-92MI-mediated cytotoxicity.							
						Skov‐3, OVCA433, TR175 and Daudi, Biopsies									MHC, binding affinity							
						SMMC7721, BEL7402, HEP3									migration,  CCL22, CXCL9, CXCL10 and CXCL12, N gamma and TNF alpha							
						SNK-6, SNT-8, and SNK-1									migration,  S1P receptor 							
						SUNE1, 5–8F, S18, S26 and CNE2									migration, extravasion							
						SV-BR-1-GM									migration, invasion, proliferation. morphology, β-catenin/TCF4							
						SW480 									migration, Lymphocytes levels, correlation							
						SW480 cells and CT-26									miR-3127-5p/p-STAT3, PD-L1, cell viability							
						SW480 or SW620									MIR21,  CD3(+), CD8(+), CD45RO (PTPRC)(+), and FOXP3(+) T cells							
						SW480, Caco-2, HKE3, 22Rv11, VCaP and LNCaP									MLH1, MSH2, MSH6, and PMS2, CD8, programmed cell death protein 1 (PD-1), and programmed death-ligand 1 (PD-L1)) and p53							
						SW480, SW620, HCT-116									mTOR, MAPK, PD-1/PD-L1							
						SW620 									MUC-1, prolifetration							
						T cell									MUC18, incasion, migration							
						T cells									mutation profile							
						T cells from ascites Lymphocytes									mutational analyses, somatic point mutations, small insertions and deletions, mutational signatures, and somatic copy number alterations							
						T cells, Three HPV(+) cell lines (UM-SCC-2, UM-SCC-47and UPCI:SCC-90, HPV(−) cell lines (PCI-13, PCI-30)									MYC, PD-L1, IFN-gamma							
						T-cells									MYCN, NKG2D , DNAM1, correlation							
						T-cells, PBMCs									neoepitopes in cancer							
						T-Regs									NF-κB/β-catenin and STAT3/IL-6 Pathways							
						T24									NKG2D , MICA, MICB, ULBP-2, and ULBP-3, MMP-9, correlation, RNA profile							
						T24, UM-UC-3, J82, RT-112, RT4, and SW780									NKG2D, IL-2, BCG, degranulation, IFNγ, citotoxicity							
						TC-1									NKp30, NKp44 and NKp46, and perforin, citotoxicity							
						TC-71, SK-N-MC, MHH-NB11									NLRC5 and PD-L1 							
						TE-1, Eca-109 and Eca-9706, Biopsies									numerical simulations and the classical linear stability analysis							
						Tet-21/N cell line									NY-ESO-1							
						THP-1 (Human acute monocytic leukemia), A-549, T2, U937, and MCF-7									NY-ESO-1-, MAGE-A3-, MAGE-A1- and β-actin, CTLA-4-, PD-1-, PD-L1							
						TIB-152, AKR-209									NY-ESO-1, CA-15–3, CEA and survivin							
						TILs									NY-ESO-1, Cytokeratin							
						TILs, Biopsies									OCT3/4, SOX2, KLF4, and c-MYC, morphology, karyotype							
						TILs, Myeloid-derived suppressor cells									oxidative DNA damage 							
						TKIs , NCI-H1975, PC9									OY-TES-1 antigene							
						triple negative breast cancer cell									OY-TES-1, correlation							
						Tumor-associated B cells									PD-1, GDNF, JAK2-STAT1 signaling pathway							
						tumor-infiltrating Lymphocytes (TILs)									PD-1, LDH, cytotoxicity							
						U251, GL-15									PD-1, PD-L1 and T Lymphocytes Expression,  CD3 and FOXP3							
						U2OS, Colo829, Biopsies									PD-1, PD-L1, migration							
						U87-MG, LN229, 293 T, U251									PD-1, PDL-1, infiltration							
						U937, MOLT4									PD-1, RNA profile, IFN-gamma, T-Regs exhaustion							
						Vero, HT-29, SW480, C32, A375, MDA-MB-231, 4T1, HepG2, and A-549									PD-1/PD-L1, citotoxicity							
						YPK-1									PD-1/PD-L1, MAPK, citotoxicity in organoids							
						YPK2 and YPK5 									PD-1/PD-Li immune inhibitory axis, T cells							
						γδ T cells									PD-11, PD-L1, infiltration of T-cells, correlation							
															PD-L1							
															PD-L1 and EGFR 							
															PD-L1 and PD-L2, IL-2, IFN 							
															PD-L1 protein expression, tumor mutation burden, and expression of an immune gene signature,  IFN-gamma, correlation							
															PD-L1, Cell migration and invasion activity							
															PD-L1, citotoxicity,  cell viability, migration, invasion, cell cycle, apoptosis							
															PD-L1, correlation, T-cell density, B-cell density,							
															PD-L1, EMT transition							
															PD-L1, FOXP3, correlation							
															PD-L1, PD-L2, DNA methylation, RNA profile, protein profile							
															PD-L1/PD-1 pathway, cytotoxicity,  PD-1, TIM-3, and LAG-3, CD137							
															PD-L1/PD-1, citotoxixcity,  T cell activation, proliferation, secretion of IFN gamma, spheroid assay, T cell infiltration							
															PD-L2, T-cell reactivity							
															PD1-PDL1 axis and/or the CTLA4							
															PD1/PDL1,  Lymphocytes proliferation and CTL activity							
															PDL-1, correlation							
															PDL1, CD8, citotoxicity							
															peptide binding							
															perforin, citotoxicity							
															perforin, ICAM-1/TGF beta 2							
															persistency of effecto cells							
															PI3K, CLEC2							
															PI3K/Akt/mTOR , citotoxicity							
															Pin1-FOXM1, cell cycle, Colony formation							
															PLAC1/CP1, IFN-γ, cytotoxic T Lymphocytes							
															Plasminogen activator inhibitor-1, macrophages infiltration,  FAK, LRP1							
															PLK1							
															polio virus receptor and Nectin-2, whereas UL16-binding proteins , MICA/B and HLA							
															poliovirus receptor (PVR), CD155, immunotoxicity, viral propragation, cell proliferation							
															PRC2, H3K27 , migration, Chemokines ,CXCL9 and CXCL10							
															predicted clinical outcome							
															proliferation							
															proliferation,  Th1 cytokines (IFN-gamma, TNF-alpha, IL-12) and Th2 cytokines (IL-10, IL-4)							
															proliferation, amine, citolysis, viability							
															proliferation, cytotoxicity, cytolines							
															proliferation, HERV-K, cell-adhesion							
															proliferation, HLA-ABC, HLA-DR, CD80, CD86, CD83 and MUC1							
															proliferation, invasion, Phagocytosis, T-cell proliferation							
															proliferation, lysis, cytokines							
															proliferation, scFV							
															proportion of PD-Li-positive carcinoma cells, corelation							
															prostate stem cell antigen (PSCA), citotoxicity							
															protein profiling							
															PSMA, antigene binding							
															PTEN, IL-12							
															PTTG1, TGFB1/SMAD3, RNA profile, migration, invation, CyclinD1 and MMP-2							
															R-CHOP variants							
															RAS, RAF, ERK, AKT, proliferation, citotoxicity							
															regulatory T cells count, CD39, Foxp3,  ICOS, PD-L1 and CTLA-4							
															RET/PTC3 , IDO1, TREG density, correlation,STAT1-IRF1 pathway							
															Rhein, citotoxicity, effector Lymphocytes , HIF-1							
															RNA profile							
															RNA profile,  E2, E6, and E7 antigens, PD-1, IDO-1, citotoxicity, T-cell							
															RNA profile, CD3, FoxP3							
															RNA profile, CTLA4							
															RNA profile, mutation profile							
															RNA profiling, 16S rRNA, lysosomal associated membrane protein 3 (LAMP3), STAT1, TAP1, intratumor microbiota							
															RNA profiling, immune profile, mutational rate, neoantigen formation, and MMR status							
															RNA profiling, JAK2, JAK3, 							
															ROR1							
															ROR1, 5T4, CAIX, Nanog, OCT4, LDH , IFN-γ secretion, degranulation							
															secreted kynurenine 							
															secreted MMP1, MMP7, MMP9, IL-6, VEGFA, IL-l alpha, TNF-alpha, GM-CSF, IL-1RA, and IL-8, PDL1, CD47, FASL, and IDO							
															sensitivity to NK, citotoxicity, apoptosis							
															Siglec-7 and Siglec-9, citotoxicity							
															signaling pathways, gene transactivation, cell viability, lactate dehydrogenase and HMGB1 release							
															signatures of T cell dysfunction and exclusion							
															single T cells transcriptional profile							
															SMAD5, IFNγ, DNA profile, mutation profile 							
															SOX-2							
															SPANX-CD, MAGEB2, MAGEA1, MAGEB6, and CXORF48 , CXORF48, MAGEB6, and CRISP2							
															sperm protein 17							
															spheroid formation, citotoxicity, sNKG2D 							
															SS1P							
															stability of the tumor-free equilibrium							
															STAT3 , T cells IFN gamma and granzyme-B							
															STAT3, RNA profiling							
															STEAP1 and STEAP1B							
															T cell activation							
															T cell activation and proliferation, citotoxicity							
															T cell activation, IL-2, IL-10, and INF-gamma, PD-L1, IDO-1							
															T cell activity, CD1d							
															T cell count							
															T cell count and reactivity							
															T cell counts, cytokines, IFN-gamma, IFN-alpha, IL-17							
															T cell infiltration							
															T cell proliferation							
															T cell proliferation, TGF-β and IL-10							
															T cell response							
															T cell responses 							
															T cell viability, citotoxicity							
															T cells proliferation, correlation							
															T cells, correlation, DNA profiling							
															T Lymphocytes proliferation, PSMA, 1BBL, IL-12, citotoxicity							
															T-cell infiltration							
															T-cell Infiltration, citotoxicity							
															T-cell profiling, PD-1 and IFNγ, cytokine 							
															T-cell reactivity							
															T-cell response							
															T-cell response 							
															T-cell response,  MHC class-I and class-II, major histocompatibility complex class I-related chain A/B, Fas, IL-1 beta and TNF-alpha, PD-L1							
															T-cell response, antigen HM1.24 							
															T-cell response, BTLA, HVEM							
															T-cell response, citotoxicity, PD-1, PD-L1, CEA691, IFNγ 							
															T-cell response, DNA profile							
															T-cell response, IFN-γ, TNF-α and IL-17A							
															T-cell response, migration, cytokines							
															T-cell response, myothelin, IL-2, IL-15 and IL-21,FN-gamma and TNF-alpha							
															T-cell response, PD-1 and Tim-3							
															T-cell response, PD-1, CD27, FAS, CD45RA, CCR7, correlation							
															T-cell response, phagocytosis, migration							
															T-cell response, TIL reactivity , HLA-I, CD- proteins							
															T-cell response, Ub-proteins, IFN-gamma							
															T-cell tissue cellularity, PD-L1 ,  PD-1, CD3, PD-1/PD-L1, correlation, T-cell infiltration							
															T-cell trafficking							
															T-cells count, MUC-1, brachyury, and CEA 							
															T-cells proliferation, citotoxicity, 							
															t-periodic system							
															T11 Target Structure, cells interactive dynamics							
															TAM density, correlation							
															TAP2, LMP2 and 7, HIF							
															temporal dynamics of cytotoxic T cells and cancer cells							
															TEX19							
															TGF-β							
															Th-like cytokine profiles, IL-4, 							
															TIL count, PD-L1, RNA profile							
															TILs							
															TILs count, GARP							
															TILs reactivity, T-cell receptors							
															TIM-3							
															TIM3, lymph node metastasis, CD8(+) T cells and CD11b(+) CD33(+) Myeloid-derived suppressor cells (MDSCss), 							
															TLR3, progression, invasion and immune evasion, cytotoxicity, cell viability							
															Toll-like receptor 4, IFN-gamma,  CD25, CD69 and 4-1BB, cytokines and chemokines							
															transcriptional profile							
															transcriptional profile, ARFL, correlation							
															transcriptome and genome alterations ,  PI3K/AKT pathway, AKT activity, FAS, PUMA, NOXA							
															treatment effectiveness							
															Treg immunosuppressive activity, correlation							
															Treg-like CCR7(+) mononuclear cells titer, CD45RA, CD25, FOXP3							
															TREM-1, COX-2 							
															TRL4, cytokine and chemokine							
															tryptophan and kynurenine metabolism							
															tryptophan-2,3-dioxygenase,  T-cell activation and proliferation 							
															Tumor immune dynamics							
															tumor mutational burden							
															tumor mutational burden (TMB) ,  PD1/PD-L1, correlation							
															tumor volumes							
															tumor-free equilibrium and coexisting equilibrium							
															tumor-immune dynamics after BCG instillations							
															tumor-infiltrating Lymphocytes (TIL), PD-L1, PD-1							
															tumor-infiltrating T-cells  distribution, TIm-3, PD-1,  IFN-gamma							
															tumour-immune interaction							
															Tumour-TICLs Interactions							
															ULBP2 , ADAM10 , citotoxicity							
															vaccine structure							
															VentX, Tumor-associated macrophages (TAMs)  count							
															viability, TREG:TEFF ratio, IL-10							
															viral infection, cytotoxicity							
															WEE1, immunopotentation							
															Wnt pathway,  proliferation and cytolytic activity, mTOR, Bcl-2, CD62L or CCR5							
															XAGE-1b							